
Recordati Industria Chimica e Farmaceutica S.p.A.
Recordati
Recordati Industria Chimica e Farmaceutica S.p.A. is an Italian biopharmaceutical company founded in 1926 and headquartered in Milan. It operates in specialty pharmaceuticals and rare disease therapeutics, with two reportable segments: Specialty & Primary Care (58.7% of FY2025 net revenue) and Rare Diseases (41.3%). The company employs 4,690 people as of December 31, 2025, and reported FY2025 revenue of USD 2.88 billion, net income of USD 488 million, total assets of EUR 5.252 billion, and shareholders' equity of EUR 1.92 billion. Recordati was listed on Euronext Milan under ticker REC until November 2026, when a consortium of CVC Capital Partners and Groupe Bruxelles Lambert, through acquisition vehicle Respighi BidCo S.p.A., completed a voluntary public tender offer at EUR 53.00 per share on November 9, 2026, reaching 91.9% ownership. This followed the tendering of a 46.82% stake held by Rossini S.a r.l. The company now faces a mandatory squeeze-out and delisting from Euronext Milan.
Strengths: Recordati's rare disease portfolio, contributing 41.3% of FY2025 revenue, includes orphan drugs such as Isturisa, Enjaymo, Signifor, Qarziba, Sylvant, Carbaglu, Panhematin, and Cystadrops, which command high barriers to entry and limited competition. The company operates eight manufacturing facilities globally, including two active pharmaceutical ingredient (API) chemical synthesis plants in Campoverde di Aprilia (Italy) and Cork (Ireland), and five formulation and packaging plants in Milan, Saint-Victor (France), Utebo (Spain), Cerkezkoy (Turkey), and Monastir (Tunisia), providing vertical integration and supply chain control. Commercial operations span approximately 150 countries, reaching more than 100 million Specialty & Primary Care patients and nearly 20,000 Rare Diseases patients annually, which supports scale in both segments. Recordati's established primary care brands, such as Zanidip, Zanipress, Seloken, Urorec, Eligard, Procto-Glyvenol, Lomexin, and Hexaspray, generate steady cash flows that fund rare disease expansion.
Weaknesses: The November 2026 tender offer at EUR 53.00 per share resulted in 91.9% ownership by Respighi BidCo, leaving only 2.28% in treasury shares and a small free float, which will lead to delisting and reduced public market scrutiny. This concentrated control by a financial consortium may prioritize debt servicing or exit timelines over long-term research investment. Recordati's revenue concentration in Europe is significant, with Italy, France, and Spain hosting major manufacturing and commercial operations, exposing the company to European pricing pressures and regulatory changes. The company faces competition from larger specialty pharmaceutical firms such as Ipsen, Chiesi Farmaceutici, Menarini, Almirall, Swedish Orphan Biovitrum (Sobi), Jazz Pharmaceuticals, and Hikma Pharmaceuticals, which may limit pricing power in both segments. Additionally, the rare disease segment's reliance on a limited number of orphan drugs, including Isturisa and Enjaymo, creates vulnerability to clinical setbacks or patent expirations.
Read MoreShow Less
Recordati Industria Chimica e Farmaceutica S.p.A. is an Italian biopharmaceutical company founded in 1926 and headquartered in Milan. It operates in specialty pharmaceuticals and rare disease therapeutics, with two reportable segments: Specialty & Primary Care (58.7% of FY2025 net revenue) and Rare Diseases (41.3%). The company employs 4,690 people as of December 31, 2025, and reported FY2025 revenue of USD 2.88 billion, net income of USD 488 million, total assets of EUR 5.252 billion, and shareholders' equity of EUR 1.92 billion. Recordati was listed on Euronext Milan under ticker REC until November 2026, when a consortium of CVC Capital Partners and Groupe Bruxelles Lambert, through acquisition vehicle Respighi BidCo S.p.A., completed a voluntary public tender offer at EUR 53.00 per share on November 9, 2026, reaching 91.9% ownership. This followed the tendering of a 46.82% stake held by Rossini S.a r.l. The company now faces a mandatory squeeze-out and delisting from Euronext Milan.
Strengths: Recordati's rare disease portfolio, contributing 41.3% of FY2025 revenue, includes orphan drugs such as Isturisa, Enjaymo, Signifor, Qarziba, Sylvant, Carbaglu, Panhematin, and Cystadrops, which command high barriers to entry and limited competition. The company operates eight manufacturing facilities globally, including two active pharmaceutical ingredient (API) chemical synthesis plants in Campoverde di Aprilia (Italy) and Cork (Ireland), and five formulation and packaging plants in Milan, Saint-Victor (France), Utebo (Spain), Cerkezkoy (Turkey), and Monastir (Tunisia), providing vertical integration and supply chain control. Commercial operations span approximately 150 countries, reaching more than 100 million Specialty & Primary Care patients and nearly 20,000 Rare Diseases patients annually, which supports scale in both segments. Recordati's established primary care brands, such as Zanidip, Zanipress, Seloken, Urorec, Eligard, Procto-Glyvenol, Lomexin, and Hexaspray, generate steady cash flows that fund rare disease expansion.
Weaknesses: The November 2026 tender offer at EUR 53.00 per share resulted in 91.9% ownership by Respighi BidCo, leaving only 2.28% in treasury shares and a small free float, which will lead to delisting and reduced public market scrutiny. This concentrated control by a financial consortium may prioritize debt servicing or exit timelines over long-term research investment. Recordati's revenue concentration in Europe is significant, with Italy, France, and Spain hosting major manufacturing and commercial operations, exposing the company to European pricing pressures and regulatory changes. The company faces competition from larger specialty pharmaceutical firms such as Ipsen, Chiesi Farmaceutici, Menarini, Almirall, Swedish Orphan Biovitrum (Sobi), Jazz Pharmaceuticals, and Hikma Pharmaceuticals, which may limit pricing power in both segments. Additionally, the rare disease segment's reliance on a limited number of orphan drugs, including Isturisa and Enjaymo, creates vulnerability to clinical setbacks or patent expirations.
Listed market data
REC.MI · MIL · weeklyHistory →- Market cap
- $12 B
- Share price
- EUR 52.85
- 1Y change
- +0.1%
- Recent change
- +0.4%
- Since first close
- ×178
- Revenue (TTM)
- $2.9 B
11-16
from 1995-03
Financial history
Full market history- 2026-11EUR 52.85$12 B-0.3%
- 2026-10EUR 53.00$12 B+0.7%
- 2026-09EUR 52.65$11.9 B+0.2%
- 2026-08EUR 52.55$11.9 B+1.7%
- 2026-07EUR 51.65$11.7 B+0.7%
- 2026-06EUR 51.30$11.6 B-0.4%
- 2026-05EUR 51.50$11.7 B+3.7%
- 2026-04EUR 49.64$11.2 B+1.2%
- 2026-03EUR 49.04$11.1 B+1.3%
- 2026-02EUR 48.42$11 B+4.5%
- 2026-01EUR 46.34$10.5 B-4.5%
- 2025-12EUR 48.54$11 B—
Ownership & Control
Latest available filings- Controlling entity
- Respighi BidCo S.p.A. (CVC Capital Partners & Groupe Bruxelles Lambert Consortium, incl. Rossini S.a r.l.) — 91.90%
- Company type
- Company
- Insiders
- 46.82%
- Institutions
- 35.15%(317 holders)
- Free float
- 48.38%
Percentages are of total shares outstanding, aggregated from 13F-style filings via Yahoo Finance. Institutional figures reflect US-filed positions and may undercount owners filing elsewhere. No figure is shown where none is disclosed.
In the press
All coverage →4 latest headlines- Recordati First Nine Months 2026: Net Revenue +7.5%, EBITDA +7.7%, Adjusted Net Income +6.4%globenewswire.com2026-11-10
- CVC, GBL secure over 90% of Recordati, clear path to delistingwtvbam.com2026-11-09
- Recordati: Solid Momentum of the Group Continues First Half 2026. Net Revenue +6.6%, EBITDA +8.8%, Adjusted Net Income +6.7%globenewswire.com2026-07-28
- Recordati Reports Strong Preliminary Full Year 2025 Results: Revenue +11.8%, EBITDA +14.5%, Adjusted Net Income +14.5%biospace.com2026-02-17
• Accounts for 58.7% of FY2025 net revenue, with brands such as Zanidip, Zanipress, Seloken, Urorec, Eligard, Procto-Glyvenol, Lomexin, and Hexaspray
• Serves more than 100 million patients annually across approximately 150 countries
• Includes active pharmaceutical ingredient API synthesis at plants in Campoverde di Aprilia Italy and Cork Ireland
Rare Diseases – orphan drug therapeutics
• Contributes 41.3% of FY2025 net revenue, focused on endocrinology, hemato-oncology, and metabolic disorders
• Portfolio includes Isturisa, Enjaymo, Signifor, Qarziba, Sylvant, Carbaglu, Panhematin, and Cystadrops
• Treats nearly 20,000 Rare Diseases patients annually
Manufacturing & API Synthesis – vertically integrated production
• Operates eight manufacturing facilities globally, including two API chemical synthesis plants in Campoverde di Aprilia Italy and Cork Ireland
• Five formulation and packaging plants located in Milan Italy, Saint-Victor France, Utebo Spain, Cerkezkoy Turkey, and Monastir Tunisia
• Supports both proprietary brands and third-party API supply
Commercial Operations – global reach
• Covers approximately 150 countries across EMEA, North America, Latin America, and APAC
• Direct sales forces and partnerships target hospitals, wholesalers, and pharmacies
• Employs 4,690 people as of December 31, 2025, with commercial hubs in Milan and other regional centers
Ownership & Corporate Structure – post-tender control
• Respighi BidCo S.p.A. CVC Capital Partners & Groupe Bruxelles Lambert consortium holds 91.9% following the November 9, 2026 tender offer at EUR 53.00 per share
• Treasury shares represent 2.28% 4,769,267 shares as of December 31, 2025
• Mandatory squeeze-out and delisting from Euronext Milan are underway
| Fiscal year | Revenue | Net income |
|---|---|---|
| 2025 | $2.9 B | $488 M |
| 2024 | $2.5 B | $451 M |
| 2023 | $2.3 B | $421 M |
| 2022 | $2 B | $329 M |
| 2021 | $1.9 B | $457 M |
Annual results from company filings (SEC XBRL), converted to US dollars.
Quick Facts
Headquarters
Founded
Employees
Market cap
Factories
Presence
Listing
Categories
Related
Similar listed companies
- Eli Lilly and Company· $1.1 T
- Johnson & Johnson (J&J)· $674 B
- Allergan Aesthetics· $533 B
- AbbVie Inc.· $510 B
- F. Hoffmann-La Roche AG· $381 B
- Merck & Co., Inc.· $366 B
Data Sources & Methodology
This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.
VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.
Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.
Key references: Official Website
